JOURNAL OF KAOHSIUNG MEDICAL ASSOCIATION 2012. vol.20, No.

NPC, Nasopharyngeal
carcinoma

1.0

25-50

31 40
50
97

8.3

EB

(
)
50~100

EB1966

EB

1970s 1980s

50~60%(
80~90%40~60%)

70%30% 1998

(47~78%)

2D(2D

132

conventional radiotherapy) 3D
(3D conformal radiotherapy)
(IMRT)
(IGRT)
(Tomotherapy)(Arc
therapy)

TN
X

()

(2006/5~2011/6)
67
5710
1
212025
(AJCC 6th edition)

/55
43
24

133

 JOURNAL OF KAOHSIUNG MEDICAL ASSOCIATION 2012. vol.20, No.2

CT sim
(local
control)100%

(regional neck control)

97%
(newly distant
metastases)6%
98%
PET
CTCAE
3
6%0%
3
4%0%

PET/CT sim
Planning System

PET/CT

134

EB

EB
DNA
95%

EBDNA

EBV-DNA
RT-PCR
EBV-DNA

Reference
1.
91
2.
97
3. Lin JC, Wang WY, Chen KY, et al.
Quantification of plasma Epstein-Barr
virus DNA in patients with advanced
nasopharyngeal carcinoma. New Engl J
Med 2004;350:2461-2470.

4. Wang CC, Improved local control

of nasopharyngeal carcinoma after
intracavitary brachytherapy boost. Am J
Clin Oncol. 1991 Feb;14(1):5-8.

5. R F Mould, T P H Tai, Nasopharyngeal

carcinoma: treatments and outcomes in
the 20th century. The British Journal of
Radiology, 75 (2002), 307339.

6. C. Andrew van Hasselt, Nasopharyngeal

carcinoma; 2nd edition. The Chinese
University Press.

135